[1] Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy[J]. Nat Rev Cancer, 2008, 8(4): 299-308.  doi: 10.1038/nrc2355
[2] Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase Ⅲ study comparing capeeitabine with fluomuracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF[J]. Br J Cancer, 2005, 92(11): 1976-1983.  doi: 10.1038/sj.bjc.6602572
[3] Gao DQ, Li CY, Zhao P, et al. The clinical effects of dendritic cell and cytokine-induced killer cell therapy for lung cancer after surgery[J]. Cancer Research, 2014, 74 Suppl 19: S2812.
[4] Zhang JP, Mao GH, Han YP, et al. The clinical effects of DC-CIK cells combined with chemotherapy in the treatment of advanced NSCLC[J]. The Chinese-German Journal of Clinical Oncology, 2012, 11(2): 67-71.
[5] 王金万, 孙燕, 刘永煜, 等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志, 2005, 8(4): 283-290.  doi: 10.3779/j.issn.1009-3419.2005.04.07
[6] 赵利红, 汪海岩, 赵晶, 等. DC-CIK细胞联合化疗治疗老年晚期非小细胞肺癌临床分析[J].徐州医学院学报, 2013, 33(12): 880-883.
[7] 曾金武, 冯茜茜. CIK细胞治疗晚期非小细胞肺癌50例临床观察[J].临床肺科杂志, 2014, 19(1): 118-120.
[8] 张金娥, 梁长弘, 赵振军, 等. CT肺灌注在肺结节诊断中的应用研究[J].中华放射学杂志, 2005, 39(10): 1041-1045.  doi: 10.3760/j.issn:1005-1201.2005.10.007